✦ LIBER ✦

392 - An in vivo model for multiple myeloma

✍ Scribed by M. Gramatzki; R. Burger; S. Kucher; H. Steininger; W. Baum

Book ID: 117664646
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 223 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)84823-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In vivo models of multiple myeloma (MM)

✍ Sanchez, Eric; Chen, Haiming; Berenson, James R. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 602 KB

In vivo and in silico studies on single

In vivo and in silico studies on single versus multiple transplants for multiple myeloma

✍ David Dingli; Jorge M. Pacheco; Angela Dispenzieri; Suzanne R. Hayman; Shaji K. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

Multiple myeloma in an adolescent

✍ S. C. Kaste; L. G. Ripps; F. Pedrosa; R. C. Ribeiro 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 777 KB

An expanding VISTA for bortezomib in mul

An expanding VISTA for bortezomib in multiple myeloma

✍ Cheeseman, M 📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 178 KB

Immunotherapy for multiple myeloma: insi

Immunotherapy for multiple myeloma: insights from other models

✍ F.K. Stevenson; K.C. Anderson 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 31 KB

Liposomal daunorubicin: in vitro and in

Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma

✍ G. Pratt; M. E. Wiles; A. C. Rawstron; F. E. Davies; J. A. L. Fenton; J. A. Prof 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

Liposomal encapsulation of anthracyclines is a potential method of drug targeting, altering both the antitumour activity and side-effect profile of anthracyclines. Liposomal daunorubicin (daunoxome) shows both altered pharmacokinetics and a potential for reducing dose-limiting cardiotoxicity compare